Endo Claims Opana Generic Versions Ripe For Misuse, Abuse

Law360, New York (December 3, 2012, 3:06 PM EST) -- Endo Pharmaceuticals Inc. on Friday urged a judge to force the U.S. Food and Drug Administration to determine whether the drugmaker voluntarily yanked the original version of its Opana ER painkiller from the market over tampering and abuse concerns and to suspend approval of nontamper-resistant generic versions.

Endo voluntarily recalled the original version of Opana ER in May after determining that it was susceptible to misuse and abuse — usually by crushing and snorting the pills — and a safety risk, according to a complaint and...
To view the full article, register now.